| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
73,070 |
62,808 |
$5.36M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
18,726 |
15,237 |
$386K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,336 |
2,069 |
$61K |
| J3490 |
Unclassified drugs |
481 |
469 |
$33K |
| G0467 |
Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit |
1,786 |
1,041 |
$33K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,267 |
1,186 |
$16K |
| 99215 |
Prolong outpt/office vis |
394 |
352 |
$14K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
192 |
192 |
$13K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
651 |
599 |
$12K |
| 85018 |
|
1,513 |
1,502 |
$9K |
| 81025 |
|
797 |
744 |
$9K |
| 81003 |
|
1,416 |
1,372 |
$8K |
| 90686 |
|
913 |
899 |
$7K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
307 |
307 |
$6K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
261 |
260 |
$5K |
| 0064A |
|
100 |
56 |
$5K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
400 |
359 |
$5K |
| 99173 |
|
714 |
713 |
$5K |
| 86580 |
|
830 |
826 |
$4K |
| 0012A |
|
149 |
149 |
$4K |
| 92552 |
|
752 |
751 |
$4K |
| D1206 |
Topical application of fluoride varnish |
470 |
470 |
$4K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
257 |
197 |
$3K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
184 |
176 |
$3K |
| 0011A |
|
181 |
181 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
251 |
242 |
$3K |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
210 |
182 |
$3K |
| 0072A |
|
48 |
24 |
$3K |
| 90700 |
|
179 |
179 |
$2K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
158 |
153 |
$2K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
268 |
268 |
$2K |
| A4267 |
Contraceptive supply, condom, male, each |
164 |
161 |
$2K |
| 90670 |
|
172 |
171 |
$2K |
| 0071A |
|
30 |
15 |
$2K |
| 90648 |
|
184 |
183 |
$2K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
104 |
103 |
$1K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
121 |
113 |
$1K |
| 90633 |
|
74 |
74 |
$1K |
| 90713 |
|
101 |
101 |
$1K |
| 90707 |
|
142 |
140 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
51 |
48 |
$905.99 |
| 90716 |
|
140 |
140 |
$863.80 |
| 90723 |
|
78 |
77 |
$595.98 |
| 90715 |
|
28 |
28 |
$559.69 |
| 90680 |
|
84 |
83 |
$471.96 |
| 90734 |
|
67 |
67 |
$258.60 |
| 90620 |
|
17 |
17 |
$254.94 |
| 99000 |
|
28 |
28 |
$197.00 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
211 |
210 |
$146.10 |
| 90685 |
|
12 |
12 |
$96.48 |
| 90651 |
|
58 |
58 |
$27.00 |